13F Holdings
中文EN

CASIF CASI Pharmaceuticals, Inc. Annual reports only

Pharmaceutical Preparations · OTC · SEC CIK 1962738 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-15.8%
TTM net income YoY-45.6%
TTM EPS YoY-26.7%
Revenue 3-yr CAGR-1.8%
Net income 3-yr CAGR—

Margins

Gross margin39.1%
Operating margin-138.8%
Net margin-137.6%
FCF margin-103.2%
EBITDA margin-134.3%

Returns

ROE-301.8%
ROA-60.9%
ROIC (approx.)-435.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets96.6%
Debt / equity0.00x
Current ratio1.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$20.71M$28.54M$33.88M$43.11M$30.17M
Cost of revenue$10.64M$17.39M$13.83M$15.83M$12.56M
Gross profit$10.08M$11.15M$20.05M$27.28M$17.61M
R&D expense$6.31M$8.92M$9.86M$16.00M$14.42M
SG&A expense$28.27M$23.58M$25.39M$23.45M$23.70M
Operating income-$45.01M-$39.62M-$25.08M-$34.03M-$41.52M
Interest expense———$0$2,900
Pretax income-$45.87M-$38.07M-$26.29M-$37.43M-$35.84M
Income tax—$0-$81,000$1.98M$0
Net income-$48.06M-$39.26M-$26.96M-$41.01M-$36.65M
EBITDA-$43.81M-$38.32M-$22.58M-$32.83M-$41.02M
EPS (basic)-2.59-2.56-2.02-3.01-2.69
EPS (diluted)-2.59-2.56-2.02-3.01-2.69
Weighted avg. shares (diluted)18.54M15.34M13.36M13.65M13.61M
Banking
Net interest income——$614,000$127,000$321,000
Balance sheet
Cash & equivalents$5.63M$13.47M$17.08M$47.11M$38.70M
Short-term investments——$12.01M$1.46M$9.87M
Receivables$4.09M$15.35M$9.55M$12.97M$9.80M
Inventory$1.60M$5.25M$15.88M$6.14M$1.91M
Current assets$13.46M$39.58M$59.34M$73.42M$61.97M
PP&E, net$6.97M$7.87M$9.24M$11.83M$12.71M
Intangibles$221,000$238,000$1.84M$1.06M$12.20M
Total assets$25.65M$53.67M$75.27M$96.23M$138.30M
Current liabilities$49.67M$36.45M$16.73M$17.00M$13.19M
Short-term debt$19.19M$18.39M———
Long-term debt——$18.89M——
Total debt——$18.89M——
Total liabilities$62.93M$51.82M$51.10M$29.30M$30.34M
Shareholders' equity-$37.28M$1.85M$24.16M$44.57M$84.50M
Net debt——$1.81M——
Shares outstanding20.56M15.49M13.38M13.46M13.98M
Cash flow statement
Operating cash flow-$20.75M-$29.22M-$19.97M-$21.09M-$26.84M
Capital expenditure$16,000$223,000$204,000$5.61M$8.95M
Free cash flow-$20.77M-$29.45M-$20.17M-$26.70M-$35.79M
Investing cash flow$951,000$11.24M-$9.67M$31.16M-$20.69M
Financing cash flow$11.25M$15.43M-$907,000-$3.27M$29.64M
Depreciation & amortization$1.20M$1.30M$2.50M$1.20M$500,000
Stock-based compensation$2.99M$1.31M$7.22M$7.01M$7.77M
Share buybacks——$278,000$3.27M—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.